DissectingandTargetingtheGrowthFactor–DependentandGrowthFactor–IndependentExtracellularSignal-RegulatedKinasePathwayinHumanSchwannomaSylwiaAmmoun,1ChristineFlaiz,1NataliaRistic,1JenniferSchuldt,2andC.OliverHanemann11ClinicalNeurobiology,PeninsulaCollegeforMedicineandDentistry,Plymouth,UnitedKingdom;and2DepartmentofNeurology,ZentrumfuerKlinischeForschung,UniversityofUlm,Ulm,GermanyAbstractSchwannomasaretumorsofthenervoussystemthatoccursporadicallyandinpatientswiththecancerpredispositionsyndromeneurofibromatosistype2(NF2).SchwannomasandallNF2-relatedtumorsarecausedbylossofthetumorsuppressormerlin.Usingourhumaninvitromodelforschwannoma,weanalyzedextracellularsignal-regulatedkinase1/2(ERK1/2)andAKTsignalingpathways,theirupstreamgrowthfactorreceptors,andtheirroleinschwan-nomacellproliferationandadhesiontofindnewsystemictherapiesforthesetumorsthat,todate,areverydifficulttotreat.WeshowherethathumanprimaryschwannomacellsshowanenhancedbasalRaf/mitogen-activatedprotein/ERKkinase/ERK1/2pathwayactivitycomparedwithhealthySchwanncells.Duetoastrongandprolongedactivationofplatelet-derivedgrowthfactorreceptorB(PDGFRB),whichishighlyoverexpressed,ERK1/2andAKTactivationwasfur-therincreasedinschwannoma,leadingtoincreasedprolifer-ation.Usingspecificinhibitors,wediscoveredthatERK1/2activationinvolvestheintegrin/focaladhesionkinase/Src/RassignalingcascadesandPDGFRB-mediatedERK1/2activationistriggeredthroughthephosphatidylinositol3-kinase/proteinkinaseC/Src/c-Rafpathway.Duetothecomplexityofsignalsleadingtoschwannomacellproliferation,potentialnewtherapeuticagentsshouldtargetseveralsignalingpathways.ThePDGFRandc-Rafinhibitorsorafenib(BAY43-9006;BayerPharmaceuticals),currentlyapprovedfortreatmentofad-vancedrenalcellcancer,inhibitsbothbasalandPDGFRB-mediatedERK1/2andAKTactivityanddecreasescellproliferationinhumanschwannomacells,suggestingthatthisdrugconstitutesapromisingtooltotreatschwannomas.Weconcludethatourschwannomainvitromodelcanbeusedtoscreenfornewtherapeutictargetsingeneralandthatsorafenibispossiblecandidateforfutureclinicaltrials.[CancerRes2008;68(13):5236–45]IntroductionSchwannomasarecommontumorsofthenervoussystemoccurringsporadicallyandinpatientswiththeinheritedcancerpredispositionsyndromeneurofibromatosistype2(NF2).SchwannomasarepurelyderivedfromSchwanncellsandlackthetumorsuppressorproteinmerlin(1).MerlinisstructurallyrelatedtotheERMfamilyproteins(ezrin,moesinandradixin;refs.2,3)thatactaslinkersbetweentheactincytoskeletonandthecellmembrane(4).Usingourinvitromodelforhumanschwannoma,wehavepreviouslyshownthatmerlinlossleadstoenhancedproliferationanddecreasedapoptosis(5),increasedcell-matrixadhesion(duetotheoverexpressionofintegrins;ref.6),anddecreasedcell-celladhesion(7).TheRhoGTPasesRac1andCdc42andtheirdownstreameffectorp21-activatedkinase(PAK)areactivatedinhumanprimaryschwannomacellsandhavebeenlinkedtotheaforementionedcharacteristicsofschwannomacells(8,9).PAKinhibitsmerlininanegativefeedbackloop(10,11),andPAKinhibitionleadstodecreasedproliferationratesandrufflinginmerlin-deficientcelllines(12).PAKcancross-talkwiththeextracellularsignal-regulatedkinase1/2(ERK1/2)signalingpathway.TheERK1/2signalingpathwayisinvolvedinratSchwanncelldedifferentiation(13),integrin-mediatedcellmotil-ity,adhesion(14),andproliferation(15).ERK1/2thatisactivatedinmouseandratschwannomacelllines(16)isinhibitedbymerlinindifferentcelllines(17).WethereforeanalyzedERK1/2pathwayinhumanprimaryschwannomasandassesseditsroleincellproliferationandadhesiontoidentifypotentialtherapeutictargetsforthetreatmentofschwannomas.MerlinadditionallyinhibitstheAKTsignalingpathway(18,19),whichisimportantforratSchwanncellsurvival(20).ActivationofERK1/2andAKTcascadesistriggeredbysurfacereceptors,suchasintegrinsandreceptortyrosinekinases(21).Onecandidateisplatelet-derivedgrowthfactorreceptorh(PDGFRh),whereininternalizationanddegradationismerlin-dependentinhumanschwannomacelllineHEI193(18).Moreover,PDGFRhinteractsdirectlywithintegrins(22),whichareoverexpressedinhumanprimaryschwannomacells(6).WethusinvestigatedtheroleofPDGFRhandothergrowthfactorreceptorsactingupstreamoftheERK1/2andAKTpathwaysinhumanprimaryschwannomacells.WeshowthatERK1/2andsubsequentenhancedproliferationoccurthroughastrongandprolongedactivationofPDGFRhafterstimulationofhumanprimaryschwannomacellswiththePDGFRh-specificagonist,platelet-derivedgrowthfactor-DD(PDGF-DD).Inaddition,schwannomacellsdisplayanenhancedbasalERK1/2activitycomparedwithSchwanncells.StrongAKTactivitywasalsoobservedinschwannomacellsuponstimulationwithPDGF-DD.Usingspecificinhibitors,wecharacterizedthemechanismsofERK1/2andAKTactivation.BasalERK1/2activationinvolvestheintegrin/focaladhesionkinase(FAK)/Src/Rassignalingcascade,andPDGFRh-mediatedERK1/2activationinvolvesthephosphatidylinositol3-kinase(PI3K)/proteinkinaseC(PKC)/Src/c-Rafpathway.Cross-talkbetweenERK1/2andAKTcascadeswasalsoobserved.Basedonourdata,weconcludethatNote:SupplementarydataforthisarticleareavailableatCancerResearchOnline(http://cancerres.aacrjournals.org/).Requestsforreprints:C.OliverHanemann,ClinicalNeurobiology,PeninsulaCollegeforMedicineandDentistry,TheJohnBullBuilding,TamarSciencePark,ResearchWay,PlymouthPL68BU,UnitedKingdom.Phone:44-1752-437-418;Fax:44-1752-517-846;E-mail:oliver.hanemann@pms.ac.uk.I2008AmericanAssociationforCancerResearch.doi:10.1158/0008-5472.CAN-07-5849CancerRes2008;68:(13).July1,20085236www.aacrjournals.orgResearchArticleResearch. on June 25, 2017. © 2008 American Association for Cancercancerres.aacrjournals.org Downloaded from multiplecascadesunderlieschwannomadevelopmentandthere-foresuggestthatpotentialtherapeuticagentsshouldtargetsev-eralsignalingpathways.WethereforetestedthePDGFRandc-Rafinhibitorsorafenib(BAY43-9006;BayerPharmaceuticals),currentlyapprovedforthetreatmentofadvancedrenalcellcancer(RCC;ref.23).WehereshowthatsorafenibinhibitsbothbasalandPDGFRh-mediatedERK1/2andAKTactivityanddecreasesproliferationofhumanschwannomacells,suggestingthatthisdrugcouldbeausefultoolinthetreatmentofschwannomas.MaterialsandMethodsIsolationandcultureofhumanSchwannandschwannomacells.HumanSchwanncellsfromhealthynervedonorsandschwannomacellsfrompatientswithNF2(afterinformedconsent)wereisolated,aspreviouslydescribed(24,25).DiagnosisofNF2wasestablishedbyclinicalcriteria(26).Cellwereharvestedandresuspendedinproliferationmedium(GFM):DMEM,10%FCS,0.5Amol/Lforskolin,10nmol/Lhheregulin,0.5mmol/L3-isobutyl-1-methylxanthine(IBMX),and2.5Ag/mLinsulin,asdescribedinref.25.Chemicals.GF109203X,LY294002,SU6656,U0126(kindlysuppliedbyProf.JyrkiKukkonen,UniversityofHelsinki),IPA-3(kindlysuppliedbyDr.JeffreyRPeterson,FoxChaseCancerCenter),AG1296,5-bromo-2¶-deoxyuridine(BrdUrd)andFTI-277werefromCalbiochem.12-O-tetrade-canoylphorbol-13-acetate(TPA),GW5074,t-octylphenoxypolyethoxyethanol(TritonX-100),polyoxyethylenesorbitanmonolaurate(Tween20),insulin,andIBMXwerefromSigma.Wortmannin(kindlysuppliedbyProf.JyrkiKukkonen,UniversityofHelsinki)wasfromTocrisCooksonLtd.,PDGF-DDfromR&DSystems.Hoechst33352wasfromMolecularProbes(Eugene),andsorafenib(BAY43-9006)waskindlysuppliedbyBayerPharmaceuticals(WestHaven).Allinhibitorswereadded30minbeforePDGF-DDstimulation.Immunoblotting.Cellswereculturedinprecoated35-mmplatestof70%confluency,serum-starvedfor24h,stimulated,andlysed(5).Theimmunoblottingwasperformed,asdescribedinrefs.8,9.Membraneswereincubatedwithantiactivemitogen-activatedproteinkinase(MAPK;anti-pThr183-pTyr185-ERK1/2;1:2,000;Promega),anti–phosphorylatedAKT(Ser473;1:500;CellSignaling),anti–phosphorylatedMAPK/ERKkinase1/2(MEK1/2)(Ser298;1:500;CellSignaling),anti–phosphorylatedMEK1/2(Ser217/221;1:500;CellSignaling),anti–phosphorylatedc-Raf(Ser338;1:500;CellSignaling),anti–phosphorylatedFAK(p-FAK;Y925;1:500;CellSignaling),anti–p-FAK(Y861;1:500;Stressgen),andanti–p-FAK(Y397;1:200:Chemicon)primaryantibodies,followedbyincubationwithappropriatehorseradishperoxidase–conjugatedsecondaryantibodies(Bio-Rad).Enhancedchemiluminescence(Amersham)wasusedfordetection.RhoGDIwasusedasaloadingcontrol,asithaspreviouslybeenshownnottoberegulatedinoursystem(27)incontrasttostandardload-ingcontrols.DensitiesofbandswerequantifiedusingFluorS-Multi-Imager(Bio-Rad).AfterstrippingandblockingtotalERK,MEK,FAK,andAKTlevelsweredeterminedusinganti–totalMAPK(ERK1/2,1:500;Promega),MEK1/2(1:500;CellSignaling),FAK(1:500;Upstate),andAKT(1:500;CellSignaling)antibodies.TheexpressionlevelsofPDGFRh,epidermalgrowthfactor(EGF)receptor(EGFR),ErbB2,andErbB3weredetectedusinganti-PDGFRh(1:500)andanti-EGFR(1:500;CellSignaling),anti-ErbB2(NeuC18;1:1000),andanti-ErbB3(1:1000)antibodiesfromSantaCruzBiotechnology.Raspull-down.Cellsweregrownuntilf70%confluence,starvedfor24h,stimulatedwith100ng/mLofPDGF-DDfor3mininthepresenceorabsenceoftheRasinhibitorFTI-277andlysed.Raspull-downexperimentswereperformedusingtheEZ-DetectRasactivationkit(Promega)accordingtomanufacturer’sprotocol.Westernblottingwasperformed,asdescribedabove,usingananti-Rasantibody(1:500;Promega).Immunocytochemistry.Cellswereserumstarvedfor24hbeforestimulation,andimmunocytochemistrywasperformed,asdescribedinrefs.8,9.Anti–activeMAPK(anti-pThr183-pTyr185-ERK1/2;1:2,000;Promega)andanti–p-FAKY397antibodieswereusedfordetectionofactiveERK1/2andFAK,respectively.AppropriateCy3orALEXAFluor488–labeledsecondaryantibodieswereused(1:500;Sigma).Adhesionassay.Cellswereseededontoprecoated24-wellplatesfor3h(28)usingdifferentconditions:DMEM,100ng/mLPDGF-DD,andGFM.Adhesionassaywasperformedasdescribed(6).BrdUrdincorporationandnuclearstainingforcellgrowth.Cellswerecultivatedon96-wellplates(Nunc)for72h,labeledwith10Amol/LBrdUrdfor24h,fixedwith4%paraformaldehyde,andincubatedwith2mol/LHCl.Cellswereblockedin2%(w/v)bovineserumalbuminandincubatedwithanti-BrdUrd(1:100;Calbiochem)followedbyALEXAFluor488–labeledsecondaryantibody(1:500;MolecularProbes).Nucleiwerestainedwith5Ag/mLHoechst33342for30min.Dividingcells(BrdUrdpositive)andtotalcellnumbers(Hoechst33342)weremanuallycounted.Allinhibitorswereadded30minbeforestimulation.Dataanalysis.Student’stwo-tailedttestwasusedforpairwisecomparisonsandANOVA,followedbyTukey’sposthoctest,wasusedformultiplecomparisons.Alltheexperimentswereperformedminimumintriplicates,whereinatleastthreeindependentbatchesofcellsfromdifferentindividualswereused.Forcellcounting,allcellsinthewellwerecounted.nsmeans(notsignificant)P>0.05,*indicatesP<0.05;**indicatesP<0.01,and***indicatesP<0.001.Significantvaluesareindicatedonlyforthedatainwhichtheresultsarenotself-evident.Infigures,meanFSEisgiven.ResultsStrongActivationofERK1/2inHumanPrimarySchwannomaCellsIncubationofserum-starvedcellswithcompletemedium(GFM)for10minutes,3hours,and24hoursproducedahigherphosphorylation/activationintensityofERK1/2inschwannomacellscomparedwithSchwanncells(Fig.1A).Inadditiontobandsat42/44kDa,wealsoobservedweakbutspecificbands(confirmedbylibrarysearchesoftherecognizedepitopeusingPhospho.ELMscreening)atf300kDa,whichdisplayedthesamepatternofactivityasthelowermolecularweightbands.ThedatainFig.1ArepresenttotalERK1/2activityincells(combineddataof42/44kDaand300kDabands).MaximalphosphorylationofERK1/2occurredinbothcelltypes10minutespoststimulationandwas3-foldhigherinschwannomacellsthaninSchwanncells.Furthermore,westimulatedschwannomacellswithvariouscomponentspresentinGFMandobservedthatserumphos-phorylatedERK1/2tothelevelscomparablewithGFM,whereasinsulin,forskolin,IBMX,andh-heregulinevokedonlyweaktomoderatesignalsevenwhenusedathighconcentrations(Fig.1BandC).Stimulationofschwannomacellswith100ng/mLPDGF-DDincreasedlevelsofphosphorylatedERK1/2by7-foldcomparedwithbasal,thesamemagnitudeasserumandGFM(Fig.1BandC).100ng/mLofEGFandfibroblastgrowthfactoracidic(FGFa),whosefunctionalitywastestedinNIH3T3andPC12cells,didnottriggerERK1/2activationinschwannomacells(Fig.1C).Inlinewiththis,schwannomacellsshownoexpressionofEGFR(SupplementaryFig.S1).Moreover,SchwannandschwannomacellsexpresssimilarlevelsofErbB2andErbB3receptors(Fig.1D)andhheregulinevenathighconcentrations(100nmol/L)displayedmuchlowerpotencytowardERK1/2activationthanPDGF-DD(100ng/mL;Fig.1BandC).PDGFRBActivationLeadstoStrongandSustainedActivationofMEK1/2andERK1/2inSchwannomaCellsPDGF-DD(100ng/mL)inducedstrongandlong-lastingMEK1/2andERK1/2activityinschwannomacells(Fig.2A).AswithGFM,inadditionto42/44kDabands,specificphosphorylatedERK1/2(p-ERK1/2)bandswerealsoobservedat300kDa.The300-kDaDissectingandTargetingERKPathwayinHumanSchwannomawww.aacrjournals.org5237CancerRes2008;68:(13).July1,2008Research. on June 25, 2017. © 2008 American Association for Cancercancerres.aacrjournals.org Downloaded from bandswerestrongeruponPDGF-DDstimulationthanuponGFMstimulationanddisplayedhigherERK1/2activityinschwannomacellscomparedwithSchwanncellsalready10minutesafterstimulationincontrastto42/44kDabandswherethesignificantdifferencewasseenonlyafter1hour(Fig.2A,comparerows2and3,top).Thespecificityof300-kDabandswasestimatedbyPhos-pho.ELMscreeningandbyusing2Amol/LTPA.DespitestrongERK1/2activityat42/44kDa,nobandat300kDawasobserveduponTPAstimulation,suggestingthat300kDabandsarespecificforPDGF-DDstimulation(Fig.2B).Thus,toshowtotalERKactivityincells,Fig.2A(bottom)showscombineddatafrom42/44kDaand300kDabands.MaximalMEK1/2/ERK1/2phosphorylationoccurred10minutesafterstimulationandpersistedatleastupto1hourat60%to70%(MEK1/2)and40%(ERK1/2)ofmaximalresponseanddeclinedtobasallevelsafter24hours.Incomparison,Schwanncellsdisplayedaweakerandonlytransientactivity,whichdeclinedtoalmostbasallevelsalreadywithin1hourafterstimulation.AKTisStronglyActivatedinSchwannomaCellsuponPDGFRBStimulationAKTshowedstrongandsustainedphosphorylation/activationatSer473inschwannomacellsuponstimulationwith100ng/mLPDGF-DD(Fig.2C)andwasobservedonlyatitsexpectedmolecularweightsize(60kDa).Maximalactivitywasreached10minutespoststimulationandremainedhigherthanbasalupto24hours.Schwanncellsincontrastdisplayedmuchweaker(maximalresponsewasapprox-imatelytwicelowerthaninschwannomacells)andtransientAKTactivity,whichdecreasedtobasallevelsatalready1hourpost-stimulation.TotalMEK1/2,ERK1/2,andAKTexpressionremainedunchangedduringallthisconditions,andnodifferencebetweenschwannomaandSchwanncellswasdetected(Fig.2A,middleandbottomandFig.2C,bottom).PDGFRBisOverexpressedinSchwannomaCellsPDGFRhisoverexpressedinschwannomacells(f2-fold)comparedwithSchwanncells(Fig.3A).Also,schwannomacellsdisplaypostponedandimpairedPDGFRhdegradationasitslevelsweredecreasedonlybyf35%within1hourofstimulationandbyf65%after24hours(Fig.3B)incontrasttoSchwanncellswherethedecreasewasmorepronounced(f85%;Fig.3CandD).ThedecreaseinPDGFRhphosphorylationwasslightlyfasterthanitsdegradation:itdecreasedbyf50%(frommaximum)1hourafterstimulationandwasabolished24hourspoststimulation(Fig.3B)followingthesamepatternasphosphorylatedMEK1/2(p-MEK1/2)andp-ERK1/2activationcourse(seeFig.2C,middleandbottom).APDGFRB-IndependentPathwayContributestoERK1/2ActivationinSchwannomaCellsInadditiontoPDGF-DDmediatedMEK1/2andERK1/2activation,ourdata(Fig.2A;0hours)alsoshowsincreasedbasallevelsofphosphorylatedMEK1/2andERK1/2inschwannomacellsFigure1.TheroleofPDGFRhinschwannomacellsignaling.A,schwannomacellsdisplaystrongandlong-lastingERK1/2activationcomparedwithSchwanncells.Time-responsecurvesforERK1/2activationuponGFM(completemedium)stimulationinSchwann(NF2+/+)andschwannoma(NF2 / )cells.BandC,PDGF-DDisapotentERK1/2activatorinschwannomacells.B,ERK1/2phosphorylationinschwannomacellsafter10minstimulationwithGFM,FCS,insulin,hheregulin,forskolin,IBMX,andPDGF-DD.C,ERK1/2phosphorylationafter10minstimulationofschwannomacellswithhheregulin,PDGF-DD,FGFa,andEGFandPC12andNIH3T3cellswithFGFaandEGF,respectively.D,ErbB2andErbB3areequallyexpressedinSchwannandschwannomacells.InallexperimentsbutD,cellswerestarvedfor24hbeforethestimulation.Thephosphorylated/activatedlevelsofERK1/2andreceptorexpressionweredetectedbyWesternblot.A,dataarenormalizedtomaximumGFMstimulation(100%).B,dataarenormalizedtothebasallevel(nonstimulatedcells).D,dataarenormalizedtoNF2+/+.AlldataarecorrectedtoloadingcontrolRhoGDI.InA,theerrorbarsat0and10mintimepointforNF2+/+arenotvisiblebecauseofverylowSD.CancerResearchCancerRes2008;68:(13).July1,20085238www.aacrjournals.orgResearch. on June 25, 2017. © 2008 American Association for Cancercancerres.aacrjournals.org Downloaded from comparedwithSchwanncells.BecausebothMEK1/2andERK1/2areequallyexpressedinSchwannandschwannomacells(seeFig.2A),wecanexcludeMEK1/2andERK1/2overexpressionasareasonforenhancedactivityandtestedthefollowingpossibilities:(a)cross-talkoftheRac/PAKpathwaywithc-Raf/MEK1/2/ERK1/2and(b)involvementofintegrinswhichareoverexpressedandactivatedinschwannomacells(6)andhavebeenreportedtoleadtotheactivationofERK1/2viatheFAK/Src/Raspathway(29).TheRac/PAKpathwayisnotinvolvedintheincreasedbasalactivityofMEK1/2andERK1/2inschwannomacells.Inbasalconditions,c-RafwasonlyfaintlyphosphorylatedatPAKphosphorylationsite(Ser338;Fig.4A,top).MEK1/2,however,wasphosphorylatedatSer298(PAKphosphorylationsite)inbothSchwannandschwannomacells,butnodifferenceinthephosphorylationintensitywasobservedbetweenthesetwocelltypes(Fig.4A,middle).Additionally,PAKinhibitorIPA-3didnotdecreasebasalERK1/2activity.TheERK1/2activitywasinsteadpotentiated,whichpossiblyoccurredduetocellularstress(Fig.4A,bottom)ashasbeenobservedpreviously(30).Thus,itisunlikelythatPAKcontributestotheenhancedbasalERK1/2activation.IncreasedbasalMEK1/2andERK1/2activityinschwan-nomacellsismediatedviatheintegrin/FAK/src/Raspathway.WethuslookedattheFAK/Src/Raspathway.IncreasedRas-GTPlevels,indicativeforRasactivity,weredetectedbyRaspull-downanalysesinserum-starvedschwannomacellscomparedwithSchwanncells(Fig.4B).TocouplebasalMEK1/2activitytoRasandSrc,weusedH-RasinhibitorfarnesylproteintransferaseinhibitorFTI-277andselectiveSrcfamilykinaseinhibitorSU6656(4Amol/L).Bothinhibitorsdecreasedsignificantlybasalp-MEK1/2levels,suggestingRasandSrctobeinvolvedinthepathwaytowardbasalMEK1/2activation(Fig.4C).FAKisoverexpressedanddisplaysstrongbasalactivityinschwannomacells.Focaladhesionkinase(FAK)isatyrosinekinasethatisactivatedafterintegrin-mediatedattachmentoftheFigure2.Time-responsecurvesforMEK1/2,ERK1/2,andAKTphosphorylation.AandC,schwannomacellsdisplaystrongandlong-lastingactivationofMEK1/2,ERK1/2,andAKT.Schwann(NF2+/+)andschwannomacells(NF2 / )werestarvedfor24handstimulatedforthetimeindicatedwithPDGF-DD(100ng/mL).MEK1/2(A,topandmiddle),ERK1/2(A,topandbottom),andAKT(C)phosphorylation/activationwasassessedbyWesternblot.A,topandB,uponPDGF-DDstimulationofERK1/2,specificbandsat300kDa(inadditionto42/44kDa)areobserved.TPA(2Amol/L,10min)activatesERK1/2onlyatthe42/44kDalevel.A(middleandbottom)andC(bottom),theexpressionofMEK1/2,ERK1/2,andAKTremainsunchangedduringPDGF-DDstimulationanddisplaysnodifferencebetweenSchwannandschwannomacells.Cellswerestarvedfor24handstimulatedforthetimeindicatedwithPDGF-DD(100ng/mL).TheexpressionofMEK1/2,ERK1/2,andAKTwasassessedbyWesternblot.InA(bottom;p-MEK1/2andp-ERK1/2)andC(bottom;p-AKT),thedataarenormalizedtothemaximumPDGF-DDstimulation(100%),andinA(bottom;totalMEK1/2andtotalERK1/2)andC(bottom;totalAKT),thedataarenormalizedtobasalNF2+/+.Emptysquares(A,middleandbottomandC,bottom),basallevelsfor24hstimulation.AlldataarecorrectedtoloadingcontrolRhoGDI.DissectingandTargetingERKPathwayinHumanSchwannomawww.aacrjournals.org5239CancerRes2008;68:(13).July1,2008Research. on June 25, 2017. © 2008 American Association for Cancercancerres.aacrjournals.org Downloaded from cellstotheextracellularmatrixandplaysanessentialroleinintegrinsignalingandtumorgenesis(31).Upontheinteractionofintegrinswiththeextracellularmatrix,FAKisautophosphorylatedatY397.IffurtherphosphorylatedbySrcatY925,FAKislinkedtotheRas/Raf/MEK1/2/ERK1/2pathway(30),andatY861,itsautophos-phorylationisenhanced(32).OverexpressionandincreasedbasalactivityofFAKwereobservedinschwannomacellscomparedwithSchwanncells(Fig.4D).FAKwasstronglyphosphorylatedatY397(Fig.4D,second,third,andfourthpanels),Y861,andY925(Fig.4D,secondandthirdpanels)inschwannomacells.ThephosphorylationintensityofFAKatallsitesinvestigatedwasnotaffectedbyPDGF-DD(Fig.4D,thirdpanel).TofurtherinvestigatetherelationshipbetweenFAKactivation,integrins,andbasalERK1/2activity,weanalyzedthecellularlocalizationofp-ERK1/2andp-FAKusingimmunofluorescencedoublelabeling.p-ERK1/2andp-FAKY397colocalizeatfocaladhesionsinschwannomacells(Fig.4D,fourthpanel),suggestingthatthebasalERKactivationisduetointegrin-mediatedactivationoftheFAK/Src/Raspathway.PDGFRB-MediatedERK1/2ActivationEmploysPKC-Src-c-RafandInvolvesTwoDifferentCompartmentsTodefineaspecificmediatorinthePDGFRh-mediatedsignalingcascadestowardERK1/2andAKTactivationinschwannomacells,weperformedadissectionofthesepathwaysbyusingavarietyofdifferentspecificinhibitors.ThespecificityofsignalinguponPDGF-DDstimulationwasconfirmedbyusingthePDGFRhinhibitorAG1296(20and40Amol/L;Fig.5B).Wefirstfocusedon42/44kDabands.RasoftenplaysanessentialroleintheactivationoftheERK1/2viadifferentmediators(33);however,themainpathwaysareeitherviadirectcouplingtoc-Raforviaindirectc-RafactivationthroughthePI3K/phosphatidylino-sitol3-phosphate–dependentkinase-1(PDK1)/PKCcascade(34).TheadditionofPDGF-DD(100ng/mL)for3minutesdidnotfurtherenhanceRasactivity(Fig.5AandSupplementaryFig.S2A,comparerows1and2),despitestrongERK1/2activationatthattimepoint(datanotshown).Additionally,FTI-277(30Amol/L)didnotinhibitPDGF-DD–mediatedERK1/2activity(Fig.5B,top,row9andSupplementaryFig.S3,comparerows2and3),sug-gestingthatinschwannomacellsRasisactivatedindependentlyofPDGFRh.TheproperfunctionoftheFTI-277isshownviaRaspull-down(SupplementaryFig.S2AandB).WenextinvestigatedtheinvolvementofPI3K,whichactseitherviaRasorviadirectcouplingtophosphorylatedPDGFR(35),resultinginelevatedphosphatidylinositol-3,4,5-trisphosphatelev-els,PKCactivationviaPDK1,andfinallyERK1/2activation.Thenonsubtype-selectivePI3Kinhibitorswortmannin(300nmol/L)andLY294002(10Amol/L;ref.36)reducedPDGF-DD–mediatedERK1/2activationby40%to60%(Fig.5B,top,columns6and7).InthePI3K-mediatedcascadetowardactivationofERK1/2,PKCcanbeoneofthemediators.WeassessedtheroleofPKCusingtheinhibitoroftheclassicandthenovelPKCisoenzymesGF109203X(37)andbyprolongedexposureofthecellstothePKCactivatorTPA(38).BothGF109203X(10Amol/L)andTPA(100nmol/L)stronglyinhibitedPDGF-DD–mediatedERK1/2activationbyf60%and40%,respectively(Fig.5B,top,columns4and5).Figure3.Theexpression,activation,anddegradationofPDGFRhinSchwann(NF2+/+)andschwannoma(NF2 / )cells.A,PDGFRhisoverexpressedinschwannomacells.SchwannandschwannomacellswereculturedinGFMandPDGFRhexpressionestimated.BandC,thedegradationandinactivationofPDGFRhispostponedinschwannomacells.B,schwannomacellswereserumstarvedfor24handstimulatedwithPDGF-DD(100ng/mL)forthetimeindicated,andphosphorylation/activationandexpressionofPDGFRhwereestimated.CandD,Schwannandschwannomacellswereserumstarvedfor24handstimulatedwith100ng/mLPDGF-DDfor24h,andtheexpressionofPDGFRhwasestimated.Westernblotmethodwasusedinalltheexperiments.A,dataarenormalizedtoNF2+/+.B,dataarenormalizedtobasallevel(nonstimulatedcells)forPDGFRhandtothemaximumPDGF-DDstimulation(100%)forphosphorylatedPDGFRh.C,dataarenormalizedtothebasallevel(nonstimulatedcells).EmptytriangleinB,basallevelfor24hstimulation.AlldataarecorrectedtoloadingcontrolRhoGDI.CancerResearchCancerRes2008;68:(13).July1,20085240www.aacrjournals.orgResearch. on June 25, 2017. © 2008 American Association for Cancercancerres.aacrjournals.org Downloaded from SrcfamilyproteinkinasesinteractwiththeERK1/2pathwayviaphosphorylationandactivationofc-RaforPKCy(39).OurdatashowthatPDGFRhactivationinschwannomacellsleadstothephosphorylationofc-RafattheSrcphosphorylationsitesY340/341(datanotshown).WethusinvestigatedtheinvolvementofSrcinPDGF-DD–mediatedERK1/2activationusingtheselectiveSrcfamilykinaseinhibitorSU6656(4Amol/L)thatstronglyinhibitedERK1/2activity(Fig.5B,top,column8).Figure4.DissectionofthesignalingpathwaytowardbasalERK1/2activationinschwannomacells.Thefollowingmoleculeswereinvestigated:PAK(A)Ras(BandC),Src(C),andFAK(D).Inallexperiments,thecellswereserumstarvedfor24h,followedbystimulationfor10minwithcompletemedium(GFM;A)and100ng/mLPDGF-DD(D,thirdpanel).WesternblotmethodwasusedinallexperimentsbutD(fourthpanel),Raspull-downwasusedinB,andimmunocytochemistryinD,fourthpanel.A,PAKisnotinvolvedinERK1/2activationinbasalconditions.Schwannomacellswerestarvedfor24handstimulatedwithGFMfor10min.Thebasal-andGFM-stimulatedphosphorylationofc-RafSer338(PAKphosphorylationsite)andbasallevelsofphosphorylatedMEK1/2Ser298(PAKphosphorylationsite)inschwannomacellswereestimatedbyWesternblot(A,topandmiddle).CellswerepretreatedwiththePAKinhibitorIPA-3(20Amol/L)for10minandlysed,andthelevelsofbasalERK1/2weredetermined(A,bottom).B,Rasisstronglyactivatedinschwannomacellsinserum-freeconditions.ActiveRas(Ras-GTP)levelsinSchwann(NF2+/+)andschwannoma(NF2 / )cellswereestimatedbyRaspull-downandWesternblotafterthecellswereserumstarvedfor24h.C,RasandSrcareinvolvedinMEK1/2activationinbasalconditions.CellswerepretreatedwithfarnesylproteintransferaseinhibitorFTI-277(30Amol/L)andwithSrcinhibitorSU6656(4Amol/L)for30min,andthelevelofphosphorylatedMEK1/2wasdetermined.D,FAKisoverexpressedandstronglyactivatedinschwannomacells.FAKexpressioninSchwann(NF2+/+)andschwannoma(NF2 / )cellswasestimatedbyWesternblotafterthecellswereserumstarvedfor24h(firstpanel).FAKisstronglyphosphorylated/activatedinschwannomacells(NF2 / )comparedwithSchwanncells(NF2+/+).Thecellswereserumstarvedfor24h,andthelevelsofphosphorylated/activatedFAK(Y397,Y861,andY925)inSchwannandschwannomacellswereestimatedbyWesternblot(secondpanel).BasalFAKactivityisnotfurtherregulatedbyPDGF-DD.Thecellswereserumstarvedfor24handstimulatedfor10minwith100ng/mLPDGF-DD.Thebasal-andPDGF-DD–stimulatedlevelsofp-FAK(Y397,Y861,andY925)inschwannomacellswereestimatedbyWesternblot(thirdpanel).PhosphorylatedERK1/2andp-FAKcolocalizeatfocaladhesionsinschwannomacells.Thecolocalizationofp-FAKwithphosphorylatedERK1/2infocaladhesionswasperformedaftercellswereserumstarvedfor24h.Whitearrowheads,colocalizingp-ERK1/2andp-FAKY397inthefocaladhesions(fourthpanel).BandD(firstandsecondpanels),dataarenormalizedtoNF2+/+.CandD(thirdpanel),dataarenormalizedtothebasal(nonstimulatedcells).DottedlinesinC,noninhibitedbasalresponseandcomparisonstononinhibitedresponse(100%).AllWesternblotdataarecorrectedtoloadingcontrolRhoGDI.DissectingandTargetingERKPathwayinHumanSchwannomawww.aacrjournals.org5241CancerRes2008;68:(13).July1,2008Research. on June 25, 2017. © 2008 American Association for Cancercancerres.aacrjournals.org Downloaded from Additionally,weexploredtheinvolvementofc-RafusingthespecificinhibitorGW5074(5Amol/L)thatdecreasedERK1/2activityby80%(Fig.5B,top,column2).PAKisnotinvolvedinPDGFRh-mediatedERK1/2activationinschwannomacells,asPDGF-DDtreatmentdidnotleadtophosphorylationofeitherc-RafatthePAKphosphorylationsite(Ser338)orMEK1/2atthePAKphosphorylationsite(Ser298;Fig.5C,firstandsecondpanels).MoreoverPAKinhibitorIPA-3displayednoeffectonPDGF-DD–stimulatedactivityofMEK1/2andERK1/2(Fig.5C,thirdpanel,lines1and3)excludingPAKasamediatorofthisERK1/2cascadeactivation.UsingthesameinhibitorsasforinvestigationoftheERK1/2pathway,weshowthatPDGF-DD–mediatedAKTactivationfollowsthetraditionalpathwayengagingPI3Ksincetheinhibitorswortman-nin(300nmol/L)andLY294002(10Amol/L)stronglyinhibitedAKTphosphorylation(Ser473;Fig.5B,bottom,columns7and8).Thus,PDGFRh-mediatedERK1/2activationdisplayedatthe42/44kDalevelisindependentofRasandPAKbutusesPI3K-PKC-Src-c-Raf–dependentpathwayandcross-talkwithAKTatthelevelofPI3K.Despitesimilarities,suchasinvolvementofc-Raf,PKC,andSrc(Fig.5B,comparetopandmiddle,columns2,4,5,and8)andbypassingRas(Fig.5B,comparetopandmiddle,column9)theactivityoftheERK1/2pathwayat42/44kDaand300kDadifferregardingtheinvolvementofMEK1/2,PI3K(Fig.5B,comparetopandmiddle,columns3,6,and7),andPAK(Fig.5C,thirdpanel,lines2and3).IncontrasttoERK1/2activationatthe42/44kDalevelthatdependsonPI3KandMEK1/2,the300-kDabandsareindependentfromthosekinases.TheengagementofPAKalsodiffersbecausePDGF-DDmediatedERK1/2activityatthe300-kDalevelisalmostcompletelyinhibitedbythePAKinhibitorIPA-3(Fig.5Cthirdpanel,line2)whereasthis,at42/44kDa,wasunaffected(Fig.5C,thirdpanel,line3).AdditionaldataobtainedbyimmunocytochemistryshowedthatIPA-3completelyabolishedtheERK1/2activityinfocaladhesionsandmembraneandalsoeliminatedthep-ERK1/2clusteringinthedot-likestructuresinthecytosol.However,thetotalERK1/2activityinthecytosolwasunaffected,thusconfirmingWesternblotdataandsuggestingPAKactingasascaffoldinacomplexcontainingERK(Fig.5C,fourthFigure5.ThedissectionofthePDGF-DD–mediatedcascadesinschwannomacells.TheERK1/2signalingpathwaywasinvestigatedbyanalyzingtheinvolvementofRas(AandB);MEK1/2,PKC,PI3K,andSrc(B);PDGFRhandc-Raf(BandD);andPAK(C).TheAKTsignalingpathwaywasinvestigatedbyanalyzingtheinvolvementofMEK1/2,PKC,PI3K,andSrc(B)andPDGFRhandc-Raf(BandD).Inallexperiments,thecellswereserumstarvedfor24hbeforethestimulationwithPDGF-DD(100ng/mL;A–D)orcompletemedium(GFM;C,firstpanel)for10min(A;3min).Thedetectionofphosphorylated/activatedproteinswasperformedbyWesternblottinginallexperimentsbutC(fourthpanel),whereimmunocytochemistrymethodwasused.InA,Raspull-downwasperformedbeforeWesternblotting.InB,thecellswerepretreatedwithPDGFhinhibitor(AG1296),c-Rafinhibitor(GW5074),MEK1/2inhibitor(U0126),PKCinhibitor(GF109203X),orwithPKCactivatorTPA,PI3Kinhibitors(WortmanninandLY294002),Srcinhibitor(SU6656),andfarnesylproteintransferaseinhibitor(FTI-277)beforestimulation.C,couplingofPAKtoERK1/2cascadewasestimatedusinganti-phosphorylatedc-RafSer338(firstpanel),anti–p-MEK1/2Ser298(secondpanel)antibodies,andPAKinhibitorIPA-3(20Amol/L;thirdandfourthpanels).Fourthpanel,thecellswerestimulatedwithPDGF-DD(100ng/mL)for10minwithandwithoutIPA-3(20Amol/L)andstainedforp-ERK1/2(green)andpaxillin(afocaladhesionmarker,red).Whitearrowheads,dot-likestructuresinthecytosol;redarrowheads,focaladhesions(visualizedbypaxillinstaininginred);whitearrows,membranestaining.D,cellswerepretreatedwithsorafenib(Bay43-9006)beforethestimulation.Inalltheexperiments,theinhibitorswereadded30minbeforethestimulationandTPAwasadded24hbeforethestimulationandIPA3for10min.DottedlinesinB,noninhibitedPDGF-DDresponseandcomparisonstononinhibitedresponse(100%).D,dataarenormalizedtothebasallevels(nonstimulatedcells).AllWesternblotdataarecorrectedtoloadingcontrolRhoGDI.CancerResearchCancerRes2008;68:(13).July1,20085242www.aacrjournals.orgResearch. on June 25, 2017. © 2008 American Association for Cancercancerres.aacrjournals.org Downloaded from panel).Thus,ourdataindicatethatPDGF-DD–mediatedERK1/2activationatthe300-kDalevelengagesc-Raf,PKC,src,andPAKandlocalizestothedifferentcellularcompartmentsthanactiveERK1/2observedatthe42/44kDalevel.Insummary,wefoundtwomajormechanismsconvergingtowardERK1/2activationinschwannomacells:(a)basalactivationviaintegrins/src/FAK/Rasand(b)PDGFRh-mediatedviathePI3K-PKC-c-RafandPKC-PAK-c-RafpathwayswerethefirstmentionedcrosstalkwithandstronglyactivateAKT(Fig.6D).Wethuschosesorafenib(1and10Amol/L),aninhibitorofPDGFRandc-Raf(Fig.6D)alreadyusedinclinic,whichefficientlyinhibitedbothbasal-andPDGF-DD–stimulatedERK1/2andAKTactivity(Fig.5D),suggestingthatthiscompoundhasapotentialtherapeuticeffectonschwannoma.PDGFRBInducesEnhancedCellProliferation,butnotAdhesion,viaERK1/2inSchwannomaCellsWenextassessedthefunctionalroleofPDGFRh-mediatedERK1/2activationinschwannomacells.Adhesion.First,weperformedanadhesionassay(6)wherecellswereculturedinthreedifferentconditions:DMEMonly,DMEMwith100ng/mLPDGF-DD,andcompletemedium(GFM).OnlyGFMbutnotPDFG-DDaloneinducedschwannomacelladhesion(datanotshown);thus,itisunlikelythatPDGFRhaloneplayaroleinthisprocess.Proliferation.WehavepreviouslyshownthatschwannomacellsdisplayanincreasedproliferationratecomparedwithSchwanncells(40).AsPDGFisapotentgrowthfactorinseveralcelltypes,wetesteditsmitogenicpotencyinourinvitromodel.Theadditionof100ng/mLPDGF-DDfor72hoursresultedinanincreaseoftotalcellnumber(determinedbyHoechst33342stainingofthenucleus)byf40%inschwannomacells,whereasnomitogeniceffectonSchwanncellswasdetected(Fig.6A)underourcultureconditions.AdditionalexperimentsmeasuringBrdUrdincorporationrevealedthatschwannomacellsdisplayedbasalproliferationactivity,whichwasstronglypotentiatedbyPDGF-DDbyf80%(Fig.6BandC),indicatingthatPDGF-DDisapotentmitogenforhumanprimaryschwannomacells.BothMEK1/2andPDGFRinhibitorsU0126(1Amol/L)andAG1296(20Amol/L),respectively,stronglyreducedPDGF-DD–mediatedaswellbasalcellproliferation(Fig.6B),suggestingthattheERK1/2pathwayisinvolvedinPDGFRh-mediatedproliferationinschwannomacells.Next,wetestedsorafenib(0.1,0.5,and1Amol/L),aPDGFRandc-RafinhibitorthatiscurrentlyapprovedforclinicaluseinadvancedRCC.Interestingly,0.5Amol/LsorafenibeffectivelyinhibitedPDGF-DDbutnotbasaland1Amol/LinhibitedbothPDGF-DD–mediatedandbasalproliferationinschwannomacells(Fig.6C),suggestingthatthiscomponentcouldbeusedforschwannomatreatment.DiscussionWeshowstrongandprolongedERK1/2pathwayactivationinhumanprimaryschwannomacellscomparedwithprimarySchwanncells.PDGFRhisstronglyoverexpressedinhumanprimaryschwannomacellsinagreementwithapreviousobservationinhumanschwannomatissue(18).InsulinandhFigure6.Signalingpathwaysinvolvedintheenhancedproliferationofschwannomacells.A,Schwann(NF2+/+)andschwannomacells(NF2 / )wereculturedfor72hwithorwithoutPDGF-DD.Totalcellamountwasestimatedbynuclearstainingwith5Ag/mLHoechst33342andcellcounting.BandC,schwannomacellswereincubatedwithU0126(MEK1/2inhibitor),AG1296(PDGFRhinhibitor),andU0126togetherwithAG1296(B)andsorafenib(PDGFRhandRafinhibitor;C)withandwithoutPDGF-DDfor72h.BrdUrd(10Amol/L)wasaddedduringthelast24hoftheexperiment.Theamountofproliferatingcells(BrdUrd-positive)wasassessedbycellcounting.Inallexperiments,thedataarenormalizedtothebasallevel(nonstimulatedcells).D,signalingpathwaystargetedbysorafenibinschwannomacells.MerlindeficiencyleadstotheactivationofRas,overexpressionandactivationofintegrins,andoverexpressionandpostponeddegradationofPDGFRh.RasandintegrinstriggerbasalERK1/2activityviaFAK,whichisstronglyoverexpressedandphosphorylated/activatedbySrc.BasalERK1/2activityisfurtherpotentiatedviaPDGFRh-mediatedPI3K/PKC/Src/c-Raf/MEK1/2andcascade.PAKactsasascaffoldinacomplexcontainingactiveERK1/2.DissectingandTargetingERKPathwayinHumanSchwannomawww.aacrjournals.org5243CancerRes2008;68:(13).July1,2008Research. on June 25, 2017. © 2008 American Association for Cancercancerres.aacrjournals.org Downloaded from heregulinactivateERK1/2onlyweakly,evenwhenusedathighconcentrations.FGFaandEGFfailtoactivateERK1/2.Additionally,theexpressionlevelsofErbB2andErbB3receptorsareequalinhumanschwannomaandSchwanncells.EGFRispresentintheratschwannomacelllineRT4(datanotshown),butnotinhumanprimarySchwannandschwannomacells.Thus,PDGFRhisacrucialreceptorsignalingthroughERK1/2pathwayinhumanschwannoma.InadditiontotheactivationoftheERK1/2pathway,PDGF-DDalsoevokesastrongandprolongedAKTresponseinschwannomacellscomparedwithSchwanncells.AlthoughPDGFRhisimportantfortheactivationoftheAKTpathway,asshownhere,wecannotexcludethat,indifferentphysiologicmilieu,othergrowthfactorscouldalsobeinvolvedinactivationofthispathway.PDGFRhdisplaysapostponeddegradationinschwannomacellscomparedwithSchwanncells,inagreementwithapreviousstudyonhumanschwannomacelllineHEI193(18).Thereceptoractivityisprolongedand,1hourafterstimulation,decreasedonlyby50%ofmaximumresponse.ThekineticsofPDGFRdeactivationisusuallymuchfaster,asshowninfibroblasts,wherealready20minutesafterstimulationtheactivitydroppedby75%(41).Ourdatasuggestthatoneoffunctionsofmerlinistoregulatethereceptoractivity.PDGFRhphosphorylation/activitydisplaythesamepatternasMEK1/2andERK1/2activity,butdivergefromAKT,whichexhibitstrongactivityeven24hoursafterstimulation.Thus,inschwannomacells,AKTactivationisregulatednotonlyatthePDGFRhlevelbutpossiblyalsobypositivefeedbackmechanismsdownstreamofthereceptor,e.g.,saturationofPI3Kactivity(41),prolongationofsignalinginendosomes(42),oractivationofphosphataseinhibitors(43).ThesehumandataextendtheobservationsmadeintheratschwannomacelllineRT4andinamouseNF2 / Schwanncellline,wherereceptorexpres-sionandfunctionwerenotaffectedbymerlin(16).Inadditiontostrongandlong-lastingPDGF-DD–mediatedMEK1/2andERK1/2activity,schwannomacellsdisplaystrongerbasalactivityofthesekinasescomparedwithSchwanncells.ThiscouldinvolveeitherRac/PAKorintegrin-mediatedpathways.PAKcanbeexcludedasanactivatorofERK1/2at42/44kDalevel,whichisthemainERK1/2bandinbasalconditions,asc-RafisnotphosphorylatedatitsPAKphosphorylationsite(Ser338)andanalysisofthePAK-dependentphosphorylationsiteonMEK1/2(Ser298)showsthatschwannomaandSchwanncellsdisplaysimilarphosphorylationlevels.Also,thePAKinhibitorIPA-3inhibitedneitherbasal-norPDGF-DD–stimulatedMEK1/2andERK1/2activity.ThisisanunexpectedfindingbecausetheRac1/PAKpathwayisstronglyup-regulatedinschwannomacells(8)andPAKisknowntoactasascaffoldtoenhanceERK1/2activity(44).However,wefoundinsteadthatERK1/2activityatthe300-kDalevel,prominentafterPDGFstimulation,isdependentfromPAKthatlikelyactsasascaffold.Moreover,theactivationoftheERK1/2atthe300-kDaleveldisplaysalsootherdifferencesfromthisat42/44kDa,asitbypassesPI3KandMEK1/2.Apotentialexplanationcouldbehiddenbindingsitesforthoseinhibitorscausedbycomplexformation.Immunocytochemistryalsoshowthedifferentialdistributionofp-ERK1/2inschwannomacells(nucleus,cytosol,membrane,andfocaladhesions).OurdatathussuggestthatPDGF-DDmediatestheactivationofERK1/2indifferentcellularcompartmentswhichdisplaydifferentmolecularbackground.Wenexttestedtheroleofintegrinsthatareup-regulatedinschwannoma(6)andmayactivateERK1/2viatheFAK/src/Raspathway(29).WedetectedenhancedbasalactivityofRas,MEK1/2,andERK1/2andincreasedexpressionandactivationofFAKinschwannomacells.Additionally,p-FAKcolocalizeswithp-ERK1/2infocaladhesions.Moreover,blockingofRasandSrcinhibitbasalMEK1/2activity.Takentogether,theseresultsindicatethatinteg-rinsarelikelytocontributetoERK1/2activationinschwannomacellsviatheFAK/src/Raspathwayunderbasalconditions.Wethinkthatinbasalconditionsschwannomacellsdisplayactivationoftheintegrin/FAK/Srccascade,aswellasincreasedlevelsofactiveRas,which,uponcouplingtop-FAK(Y925),leadstoactivationofERK1/2.AsthestimulationofPDGFRhstronglypotentiatesERK1/2andAKTactivity,weconsiderthatthisreceptoranditsdownstreamsignalingpathwaysisimportantforschwannomadevelopment.Todefineapotentialtherapeutictargetforschwannomatreatment,weperformedadissectionofthecascadesdownstreamofPDGFRhinadditiontobasalactivation.OurdatasuggestcooperationbetweenPI3K,PKC,andSrcinPDGF-DD–mediatedERK1/2activation.AlthoughRasisstronglyactivatedinschwannomacellsandimplicatedinbasalsignalingtowardERK1/2activation,itisnotfurtheractivatedbyPDGF-DDandisnotinvolvedinthePDGFRh-mediatedpathway.ThiscouldbeexplainedbyapossibleuncouplingofRasfromthereceptor.DifferentRasisoformslocalizetodistinctmicrodomainswithinplasmamembraneanddifferentintracellularcompartmentsleadingtodiversesignaloutputsdespiteinteractionwithsimilaractivatorsandeffectors(45).RasinsensitivitytoPDGF-DDcouldalsobeexplainedbyeithersaturatedbasalactivityofRasoranegativefeedbackfrombasalERK1/2toGrb2-Sos(Ras-GEF;ref.46).Ourdatasomehowcontradictspreviousfindings,showingRasinvolvedinPDGFRh-mediatedERK1/2activation(16).ThisdiscrepancymaybedowntotheuseofratschwannomacelllinecausedbydifferentmutationanddisplayingmalignantpropertiesbyMorrisonandcolleagues,whereaswefocusedourstudyonprimaryhumanschwannoma.WeshowthatPDGF-DDengagesdifferentpathwaystoactivateERK1/2thatislocalizedtodifferentintracellularcompartmentsanddetectedatdifferentmolecularweightlevelsbyWesternblot.Thep-ERK1/2pathwayat42/44kDa(cytosol)favorsamodelinwhichc-RafisactivatedbySrcandPKC,wherethelaterisactivatedbyPI3K(viaPDK1),whichdirectlybindstophosphor-ylated/activatedPDGFRh(Fig.6D;refs.47,48).PI3KactsalsoasaconvergencepointtotheactivationofAKT(Fig.6D).Thep-ERK1/2pathwayat300-kDalevel(focaladhesions)engagesc-Raf,PKC,Src,andPAK.OurdatathusfittopreviousobservationsshowingthatERK1/2activityistightlyregulatedbymerlin(17)andinvolvedinratSchwanncellsdedifferentiation(13)andintegrin-mediatedcellmotilityandadhesion(14),whichisdramaticallydisregulatedinmerlin-deficientschwannomacells(6).WhereastransientERK1/2activityisimportantfornormalcellfunction,astrongandlong-lastingERK1/2activationcanbemitogenic(49,50).WeshowincreasedproliferationofschwannomacellsuponstimulationwithPDGF-DD,whereasnoeffectswereobservedinSchwanncells.ThiscouldbeexplainedeitherbytheshortandweakERK1/2activityinthosecellsorarequirementforadditionalfactorsintheculturemedium,suchasinsulin-likegrowthfactors(51).InhibitionofMEK1/2decreasesPDGF-DD–mediatedproliferationtobasallevels,suggestingthatERK1/2path-wayisinvolvedinthisprocess.Additionally,bothMEK1/2andPDGFRhinhibitionsignificantlyinhibitedbasalcellproliferation,suggestingthatboththeintegrin/FAK/src/RascascadeandPDGFRh-mediatedsignaling,possiblyviaautocrinemechanisms,areinvolvedinschwannomacellproliferation.CancerResearchCancerRes2008;68:(13).July1,20085244www.aacrjournals.orgResearch. on June 25, 2017. © 2008 American Association for Cancercancerres.aacrjournals.org Downloaded from Basedonthisevidence,weconsiderPDGFRh-mediatedsignalingtobeinvolvedinschwannomadevelopment.Additionally,theintegrin-mediatedFAK/src/RascascadecontributestobasalERK1/2activity,therebypotentiatingthePDGFRh-specificpathway(Fig.6D;ref.16).Becausedifferentpathwaysareinvolvedinschwannomacellproliferation,wesuggestthatacombinedtherapytargetingdifferentproteinsmightbeappropriatefortreatingschwannoma.Promisingtherapeuticagentincludesorafenib,aPDGFRandRafinhibitoralreadyapprovedforuseinpatientswithadvancedRCC,asitinhibitsefficientlybothbasalandPDGF-DD–mediatedERK1/2andAKTactivationandproliferationinhumanprimaryschwannomacells.DisclosureofPotentialConflictsofInterestNopotentialconflictsofinterestweredisclosed.AcknowledgmentsReceived10/11/2007;revised3/4/2008;accepted4/9/2008.Grantsupport:Children’sTumorFoundationandPeninsulaCollegeofMedicineandDentistry.Thecostsofpublicationofthisarticleweredefrayedinpartbythepaymentofpagecharges.Thisarticlemustthereforebeherebymarkedadvertisementinaccordancewith18U.S.C.Section1734solelytoindicatethisfact.WethankProf.JyrkiKukkonen(UniversityofHelsinki)forGF109203X,LY294002,SU6656,U0126,andwortmannin,BayerPharmaceuticalsforsorafenib(BAY43-9006),andDr.JeffreyRPeterson(FoxChaseCancerCenter)forIPA-3.DissectingandTargetingERKPathwayinHumanSchwannomawww.aacrjournals.org5245CancerRes2008;68:(13).July1,2008References1.McClatcheyAI,GiovanniniM.Membraneorganizationandtumorigenesis-theNF2tumorsuppressor,Merlin.GenesDev2005;19:2265–77.2.RouleauGA,MerelP,LutchmanM,etal.Alterationinanewgeneencodingaputativemembrane-organizingproteincausesneuro-fibromatosistype2(seecom-ments).Nature1993;363:515–21.3.TrofatterJA,MacCollinMM,RutterJL,etal.Anovelmoesin-,ezrin-,radixin-likegeneisacandidatefortheneurofibromatosis2tumorsuppressor.Cell1993;75:826.4.BretscherA,EdwardsK,FehonRG.ERMproteinsandmerlin:integratorsatthecellcortex.NatRevMolCellBiol2002;3:586–99.5.UtermarkT,KaempchenK,AntoniadisG,HanemannCO.Reducedapoptosisratesinhumanschwannomas.BrainPathol2005;15:17–22.6.UtermarkT,KaempchenK,HanemannCO.Patholog-icaladhesionofprimaryhumanschwannomacellsisdependentonalteredexpressionofintegrins.BrainPathol2003;13:352–63.7.FlaizC,UtermarkT,ParkinsonDB,PoetschA,HanemannCO.Impairedintercellularadhesionandimmatureadherensjunctionsinmerlin-deficienthumanprimaryschwannomacells.Glia2008;56:506–15.8.KaempchenK,MielkeK,UtermarkT,LangmesserS,HanemannCO.UpregulationoftheRac1/JNKsignalingpathwayinprimaryhumanschwannomacells.HumMolGenet2003;12:1211–21.9.FlaizC,KaempchenK,MatthiesC,HanemannCO.Actin-richprotrusionsandnonlocalizedGTPaseactiva-tioninmerlin-deficientschwannomas.JNeuropatholExpNeurol2007;66:608–16.10.KissilJL,WilkerEW,JohnsonKC,EckmanMS,YaffeMB,JacksT.Merlin,theproductoftheNf2tumorsuppressorgene,isaninhibitorofthep21-activatedkinase,Pak1.MolCell2003;12:841–9.11.HirokawaY,TikooA,HuynhJ,etal.Acluetothetherapyofneurofibromatosistype2:NF2/merlinisaPAK1inhibitor.CancerJ2004;10:20–6.12.PeltonPD,ShermanLS,RizviTA,etal.Rufflingmembrane,stressfiber,cellspreadingandproliferationabnormalitiesinhumanschwannomacells.Oncogene1998;17:2195–209.13.HarrisinghMC,Perez-NadalesE,ParkinsonDB,MalcolmDS,MudgeAW,LloydAC.TheRas/Raf/ERKsignallingpathwaydrivesSchwanncelldedifferentia-tion.EMBOJ2004;23:3061–71.14.SawhneyRS,CooksonMM,OmarY,HauserJ,BrattainMG.Integrina2-mediatedERKandcalpainactivationplayacriticalroleincelladhesionandmotilityviafocaladhesionkinasesignaling:identifica-tionofanovelsignalingpathway.JBiolChem2006;281:8497–510.15.MelocheS,PouyssegurJ.TheERK1/2mitogen-activat-edproteinkinasepathwayasamasterregulatoroftheG1-toS-phasetransition.Oncogene2007;26:3227–39.16.MorrisonH,SperkaT,ManentJ,GiovanniniM,PontaH,HerrlichP.Merlin/neurofibromatosistype2sup-pressesgrowthbyinhibitingtheactivationofRasandRac.CancerRes2007;67:520–7.17.LimJY,KimH,JeunSS,KangSG,LeeKJ.Merlininhibitsgrowthhormone-regulatedRaf-ERKspathwaysbybindingtoGrb2protein.BiochemBiophysResCommun2006;340:1151–7.18.FraenzerJT,PanH,MinimoL,Jr.,SmithGM,KnauerD,HungG.OverexpressionoftheNF2geneinhibitsschwannomacellproliferationthroughpromotingPDGFRdegradation.IntJOncol2003;23:1493–500.19.RongR,TangX,GutmannDH,YeK.Neurofibroma-tosis2(NF2)tumorsuppressormerlininhibitsphos-phatidylinositol3-kinasethroughbindingtoPIKE-L.ProcNatlAcadSciUSA2004;101:18200–5.20.LiY,TennekoonGI,BirnbaumM,MarchionniMA,RutkowskiJL.NeuregulinsignalingthroughaPI3K/Akt/BadpathwayinSchwanncellsurvival.MolCellNeurosci2001;17:761–7.21.MeierF,SchittekB,BuschS,etal.TheRAS/RAF/MEK/ERKandPI3K/AKTsignalingpathwayspresentmoleculartargetsfortheeffectivetreatmentofad-vancedmelanoma.FrontBiosci2005;10:2986–3001.22.HeldinCH,WestermarkB.Mechanismofactionandinvivoroleofplatelet-derivedgrowthfactor.PhysiolRev1999;79:1283–316.23.EscudierB,EisenT,StadlerWM,etal.Sorafenibinadvancedclear-cellrenal-cellcarcinoma.NEnglJMed2007;356:125–34.24.HanemannCO,RosenbaumC,KupferS,WoschS,StoegbauerF,MuellerHW.ImprovedculturemethodstoexpandSchwanncellswithalteredgrowthbehaviourfromCMT1Apatients.GLIA1998;23:89–98.25.RosenbaumC,KluweL,MautnerVF,FriedrichRE,MuellerHW,HanemannCO.Isolationandcharacter-izationofSchwanncellsfromneurofibromatosistype2patients.NeurobiolDis1998;5:55–64.26.NationalInstitutesofHealthConsensusDevelop-mentConferenceStatementonAcousticNeuroma,December11-13,1991.TheConsensusDevelopmentPanel.ArchNeurol1994;51:201–7.27.HanemannCO,Bartelt-KirbachB,DieboldR,KampchenK,LangmesserS,UtermarkT.DifferentialgeneexpressionbetweenhumanschwannomaandcontrolSchwanncells.NeuropatholApplNeurobiol2006;32:605–14.28.MilnerR,WilbyM,NishimuraS,etal.DivisionoflaborofSchwanncellintegrinsduringmigrationonperipheralnerveextracellularmatrixligands.DevBiol1997;185:215–28.29.SchlaepferDD,HunterT.Focaladhesionkinaseoverexpressionenhancesras-dependentintegrinsignal-ingtoERK2/mitogen-activatedproteinkinasethroughinteractionswithandactivationofc-Src.JBiolChem1997;272:13189–95.30.DeaconSW,BeeserA,FukuiJA,etal.Anisoform-selective,small-moleculeinhibitortargetstheautoregu-latorymechanismofp21-activatedkinase.ChemBiol2008;15:322–31.31.HehlgansS,HaaseM,CordesN.Signalingviaintegrins:implicationsforcellsurvivalandanticancerstrategies.BiochimBiophysActa2007;1775:163–80.32.LeuTH,MaaMC.Tyr-863phosphorylationenhancesfocaladhesionkinaseautophosphorylationatTyr-397.Oncogene2002;21:6992–7000.33.BosJL.Allinthefamily?NewinsightsandquestionsregardinginterconnectivityofRas,Rap1andRal.EMBOJ1998;17:6776–82.34.LeGoodJA,ZieglerWH,ParekhDB,AlessiDR,CohenP,ParkerPJ.ProteinkinaseCisotypescontrolledbyphosphoinositide3-kinasethroughtheproteinkinasePDK1.Science1998;281:2042–5.35.WymannMP,ZvelebilM,LaffargueM.Phosphoinosi-tide3-kinasesignalling-whichwaytotarget?TrendsPharmacolSci2003;24:366–76.36.VlahosCJ,MatterWF,HuiKY,BrownRF.Aspecificinhibitorofphosphatidylinositol3-kinase,2-(4-morpho-linyl)-8-phenyl-4H-1-benzopyran-4-one(LY294002).JBiolChem1994;269:5241–8.37.ToullecD,PianettiP,CosteH,etal.Thebisindolylma-leimideGF109203XisapotentandselectiveinhibitorofproteinkinaseC.JBiolChem1991;266:15771–81.38.BindelsRJ,DempsterJA,RamakersPL,WillemsPH,vanOsCH.EffectofproteinkinaseCactivationanddown-regulationonactivecalciumtransport.KidneyInt1993;43:295–300.39.SteinbergSF.DistinctiveactivationmechanismsandfunctionsforproteinkinaseCdelta.BiochemJ2004;384:449–59.40.SchulzeKM,HanemannCO,MullerHW,HanenbergH.Transductionofwild-typemerlinintohumanschwannomacellsdecreasesschwannomacellgrowthandinducesapoptosis.HumMolGenet2002;11:69–76.41.ParkCS,SchneiderIC,HaughJM.Kineticanalysisofplatelet-derivedgrowthfactorreceptor/phosphoinosi-tide3-kinase/Aktsignalinginfibroblasts.JBiolChem2003;278:37064–72.42.HaughJM,LauffenburgerDA.Analysisofreceptorinternalizationasamechanismformodulatingsignaltransduction.JTheorBiol1998;195:187–218.43.HeinrichR,NeelBG,RapoportTA.Mathematicalmodelsofproteinkinasesignaltransduction.MolCell2002;9:957–70.44.BeeserA,JafferZM,HofmannC,ChernoffJ.RoleofgroupAp21-activatedkinasesinactivationofextracel-lular-regulatedkinasebygrowthfactors.JBiolChem2005;280:36609–15.45.HancockJF.Rasproteins:differentsignalsfromdifferentlocations.NatRevMolCellBiol2003;4:373–84.46.DongC,WatersSB,HoltKH,PessinJE.SOSphosphorylationanddisassociationoftheGrb2-SOScomplexbytheERKandJNKsignalingpathways.JBiolChem1996;271:6328–32.47.ChongH,VikisHG,GuanKL.MechanismsofregulatingtheRafkinasefamily.CellSignal2003;15:463–9.48.TallquistM,KazlauskasA.PDGFsignalingincellsandmice.CytokineGrowthFactorRev2004;15:205–13.49.RooversK,AssoianRK.IntegratingtheMAPkinasesignalintotheG1phasecellcyclemachinery.Bioessays2000;22:818–26.50.PouyssegurJ,VolmatV,LenormandP.Fidelityandspatio-temporalcontrolinMAPkinase(ERKs)signal-ling.BiochemPharmacol2002;64:755–63.51.StewartHJ,BradkeF,TaberneroA,MorrellD,JessenKR,MirskyR.RegulationofratSchwanncellPoexpressionandDNAsynthesisbyinsulin-likegrowthfactorsinvitro.EurJNeurosci1996;8:553–64.Research. on June 25, 2017. © 2008 American Association for Cancercancerres.aacrjournals.org Downloaded from 2008;68:5236-5245. Cancer Res(cid:160)(cid:160) Sylwia Ammoun, Christine Flaiz, Natalia Ristic, et al. (cid:160) Kinase Pathway in Human SchwannomaIndependent Extracellular Signal-Regulated-Growth FactorDependent and-Dissecting and Targeting the Growth Factor(cid:160) Updated version(cid:160)  http://cancerres.aacrjournals.org/content/68/13/5236Access the most recent version of this article at:(cid:160) MaterialSupplementary(cid:160)  http://cancerres.aacrjournals.org/content/suppl/2008/06/19/68.13.5236.DC1Access the most recent supplemental material at:(cid:160) (cid:160) (cid:160) (cid:160) (cid:160) Cited articles(cid:160)  http://cancerres.aacrjournals.org/content/68/13/5236.full.html#ref-list-1This article cites 51 articles, 17 of which you can access for free at:(cid:160) Citing articles(cid:160)  /content/68/13/5236.full.html#related-urlsThis article has been cited by 16 HighWire-hosted articles. Access the articles at:(cid:160) (cid:160) (cid:160) E-mail alerts related to this article or journal.Sign up to receive free email-alerts(cid:160) SubscriptionsReprints and (cid:160) .pubs@aacr.orgDepartment atTo order reprints of this article or to subscribe to the journal, contact the AACR Publications(cid:160) Permissions(cid:160) .permissions@aacr.orgDepartment atTo request permission to re-use all or part of this article, contact the AACR PublicationsResearch. on June 25, 2017. © 2008 American Association for Cancercancerres.aacrjournals.org Downloaded from 